We are experiencing an antimicrobial resistance (AMR) crisis, brought on by the drying up of
the antibiotic discovery pipeline and the resulting unchecked spread of resistant pathogens …

Antimicrobial resistance continues to be a public threat on a global scale. The ongoing need
to develop new antimicrobial drugs that are effective against multi-drug-resistant pathogens …

A challenge in the treatment of Staphylococcus aureus infections is the high prevalence of
methicillin-resistant S. aureus (MRSA) strains and the formation of non-growing, dormant …

Introduction Antibiotic resistance is one of the biggest public health threats worldwide.
Currently, antibiotic-resistant bacteria kill 700,000 people every year. These data represent …

Persisters refer to genetically drug susceptible quiescent (non-growing or slow growing)
bacteria that survive in stress environments such as antibiotic exposure, acidic and …

The public view on antibiotics as reliable medicines changed when reports about “resistant
superbugs” appeared in the news. While reasons for this resistance development are easily …

Therapeutic drug development is a long, expensive, and complex process that usually takes
12–15 years. In the early phases of drug discovery, in particular, there is a growing need for …

Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of
hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) …

Due to the continued emergence of resistance and a lack of new and promising antibiotics,
bacterial infection has become a major public threat. High-throughput screening (HTS) …

There is an urgent need to discover novel antimicrobial therapies. Drug repurposing can
reduce the time and cost risk associated with drug development. We report the inhibitory …